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The development of a lung cancer trials flowchart
Richard J Stephens
MRC Clinical Trials Unit, London, UK
l " International Lung Cancer Conference
The most recent report from National Cancer Research Network indicates that around 10 times more
breast cancer patients are entered into UK clinical trials than lung cancer patients. We need to
understand the reasons for this and urgently explore ways to improve accrual to lung cancer trials.
Patients may not enter trials because they have pre-conceived ideas about what treatment they want
(or do not want), although research has indicated that they do not mind being asked (indeed, that they
do not like not being asked), and generally trust the doctor's advice. The onus is therefore on clinicians
to be aware of all current trials and to identify all suitable patients. Equally patients cannot enter trials
is if there are no suitable ongoing trials. To develop a wide portfolio, the NCRI Lung Cancer Clinical
Studies Group has set up a number of disease specific subgroups and has instigated a clear process for
the proposal and development of trials ideas
In addition, a clinical trials flowchart, fitting on one-side of an A4 sheet, has been developed to (a)
remind clinicians and research nurses about ongoing trials, the relevant groups of patients and the trials
office contact details, and (b) highlight gaps in the trials portfolio, in order to aid the NCRI Lung Cancer
subgroups.
Hopefully over the next few years the procedures put in place will result in a major increase in the
number of lung cancer patients entering trials, which will ultimately improve the outcomes for this
group of patients.
PP2
Effects of hypoxia on small cell lung carcinoma cells
Matilda Munksgaard Persson, Sven P§hlman and Helen M. Pettersson
Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, University
Hospital MAS, Malmo, Sweden
Introduction: Small cell lung carcinoma (SCLC) is a very aggressive solid tumor and the 5-year survival
prognosis for these patients is only approximately 9-15%.
Regions of hypoxia (1% oxygen) often appear in solid tumors and are associated with aggressive tumor
behaviour and poor outcome in several tumor forms. Cells adapt to a hypoxic environment by changing
their gene expression profile and this affects a variety of processes in the cells.
This occurs primarily as a result of the transcription factors, hypoxia-inducible factor (HIF), which
become stable at low oxygen levels.
Objective: To characterize the adaptive capacity of SCLC cells to hypoxia and to evaluate the
importance of activation of HIF transcription factors in SCLC cells.
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Method: We cultured a panel of SCLC cell lines in hypoxic conditions and mRNA and protein expression
levels of genes known to be involved in hypoxic adaptation, were investigated by quantitative real-time
PCR and Western blotting. The expression of HIF transcription factors were also investigated
immunohistochemically in SCLC specimens.
Results and conclusion: Preliminary data indicate that the proliferation is to some extent reduced in
SCLC cells at hypoxia. Based on the investigated genes involved in hypoxlc adaptation, a moderate
response to hypoxia is induced in SCLC cells, though the cells seem to have a high adaptive capacity.
Further investigations are needed to understand how SCLC cells adapt to a hypoxic environment.
PP3
TPS3 and P21 polymorphisms and risk of lung cancer in Iranian population
Zivar Salehi, Farhad Mashayekhi and Mohammad Naji
Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran
Introduction: The TP53 tumor suppressor gene located at chromosome 17p13, is described as mutated
in 50-55% of cancer cases. TP53 plays a central role in response to DNA damage, maintaining host cell
genomic stability after carcinogenic exposure. P53 protein can be activated by or interact with many
other proteins in the signaling pathway network. Codon 72 polymorphism of the TP53 gene encodes
either arginine (CGC) or proline (Ccq and these two allelic variants are structurally and functionally
different, conferring different susceptibilities to cancer development.
P53 is also responsible for the transcriptional induction of the P21 gene, located at chromosome
6p21.2, that encodes the p21 protein. This protein, also known as WAF1/CIP1, is a cyclin kinase
inhibitor that inhibits all cyclin-dependent kinases complex, causing cell cycle arrest in the G1 phase of
the cell cycle. Mutations in either TP53 or P21 gene may affect the regulation of cellular proliferation,
increasing the susceptibility to cancer.
Objective: The aim of this study was to investigate the association of p53 and p21 polymorphisms with
susceptibility to lung cancer.
Methods: The genotypes of the Tp53 codon 72 and P21 codon 31 polymorphisms were identified using
AS-PCR and PCR-RFLP, respectively. The number of 115 patients with lung cancer and non-cancer
controls were included in this study.
Results and Conclusion: The Pro allele frequency was significantly higher among lung cancer patients
than healthy controls (P value 0.024). There was no significant difference in Pro/Arg and Arg/Arg
genotype frequency among patients and healthy controls (P value 0.041 and 0.026, respectively). The
risk Pro homozygote for lung cancer was about 2 times against homozygote with adjusted odds ratio of
2.12 (95% CI-1.13-4.01).
The p21 genotype frequencies in the non-cancer control were 0.51(Ser) and 0.49(Arg). Our data did
not demonstrate on association of Arg allele of p21 polymorphism with lung cancer risk in Iran. This
data suggested that the p21 codon 31 polymorphism may not playa significant role in cancer
susceptibility and the prognosis of lung cancer patients in Iran. p53 Pro/Pro genotype is an independent
risk factor for lung cancer in Iran.
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PP4
ERCC-l expression in non small cell lung cancers - an experience in a UK specialist centre
Ashish Narula, Laura Fulford, Philippa Munson, Mary Falzon.
Univerity College London Hospitals, Histopathology, London,UK Key words: ERCC1, Lung cancer,
cisplatin.
Introduction: Excision repair cross-complementing group 1 protein (ERCC1) is an important enzyme in
DNA repair. It is expressed in many normal tissues but recent work has shown its over expression in
non-small cell lung cancers (NSCLC), can predict resistance to cisplatin based chemotherapy regimes
and thus impact upon response to treatment and ultimately survival. These investigators developed an
immunohistochemistry based method of quantifying ERCC-1 expression in biopsies that allowed
reproducible assessment of tumours
Objective/Purpose: In this study we seek to replicate and adapt the methodology of ERCC-1
immunohistochemistry at UCLH, and develop a robust and reproducible in-house test for ERCC-1
expression in NSCLC that can be used in diagnostic surgical practice.
Method: 32 file cases of NSCLC were selected. Decreasing ERCC-1 antibody dilutions were assessed to
identify the minimum needed for reliable staining without over-retrieval of normal background
expression. Tonsil was used for control with endothelial cell expression needed for internal control. A
tumour was considered positive if >10% nuclei showed antibody staining. Patterns of staining were
compared to images from the original investigators to assess reliability.
Results and Conclusion: Antibody dilution of 1/100 was found adequate for
ERCC1 evaluation. 13/32 cases (41%) were judged positive for ERCC-1 overexpression, a similar
proportion to the literature.
Recent work suggests ERCC1 negative NSCLC respond better to cisplatin based chemotherapy with
longer disease free interval, compared to positive cases. A multicentre trial is being developed at UCLH
using this ERCC-1 immunohistochemistry to guide chemotherapy choice, and to assess any significant
benefit in patient survival.
PP 5
Palliative Radiotherapy for NSCLC Trials Protocol
Craig Martin
Norfolk and Norwich University Hospital, Oncology Department, Norwich, UK
Introduction: The only randomized trials of palliative thoracic radiotherapy (TRT) for NSCLC are studies
of dose-fractionation or timing of TRT in the patient's pathway. The consensus from the former is that,
in good performance status (PS) patients fractionated TRT gives superior survival to hypofractionated,
although symptom-control is the same, and that in poor PS patients one fraction is as effective as two
or more fractions. Also, delaying TRT until development of symptoms did not worsen survival where the
majority of patients received hypofractionated TRT.
Thus there is a huge need for randomized studies involving palliative TRT in NSCLC.
Objective: To suggest possible avenues of study.
Methods: Studies in the following topics could influence practice:
1) Whether TRT after chemotherapy in asymptomatic, good PS patients improves survival or
quality of life (QOL)
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2) Whether TRT after radiotherapy for metastatic disease in poor PS patients, without chest
symptoms, improves survival or QOL
3) Whether TRT improves respiratory function
4) Aspects of simulation: whether fluoroscopic screening improves accuracy over static screening
and whether to include adjacent nodal disease
S) Whether cetuximab or other agents given concomitantly with TRT lead to improved survival or
QOL
6) A follow-up study of symptom-control after TRT, randomized between follow-up by oncologist,
chest physician, specialist nurse or GP
Conclusion: These will be briefly discussed.
PP6
Biomarker selection in non small cell lung cancer data: early experiences from the EUELC
Lung Cancer Collaboration data sets
Zulkifli Doll, Gavin Brownl, John Field2, Andy Brassl on behalf of the EUELC Consortium.
1 School of Computer Science, The University of Manchester, UK.
2 Roy Castle Lung Cancer Research Programme, Cancer Research Centre, University of Liverpool, UK.
A number of different strategies have been developed for biomarker discovery in cancer using
microarray data. The problem that typically needs to be addressed is the scale of the data sets: we
simply do not have (or are likely to obtain) sufficient data for classical machine learning approaches for
biomarker discovery to be properly validated. We have therefore looked at new methodologies for using
existing biological knowledge to support machine learning biomarker discovery techniques based on
prior biological knowledge. This has been explored using data generated by the EUELC consortium.
Expression profiling of a subset of the EUELC lung cancer patients tumour tissue and normal adjacent
tissue has been undertaken utilizing the Agilent 44K gene chip with high quality RNA.
In the first instance we have tackled the simplest problem within the dataset - looking for biomarkers
that could distinguish between adenocarcinoma and squamous cell carcinomas. A number of machine
learning gene selection approaches were used to identify biomarkers separating the carcinoma data.
Interestingly we found a core of a few hundred genes that were consistently identified by all methods
as good potential biomarkers.
Principal Component Analysis clearly demonstrated that these genes could be used to form an effective
classifier. Pathway, gene ontology and literature (text-mining) analyses were then performed to provide
support for this set as representing plausible biomarkers. From this analysis we have developed a
framework which can provide narrative support to the clusters generated - a framework that can now
be employed in the automated Taverna E-Science workflow environment (www.mygrid.org.uk).
PP7
Continuous daily dosing of sunitinib in advanced NSCLC
Ramaswamy Govindan,l Rafael Rosell,2 Mark A. Socinski,3 Julie R. Brahmer,4 James N. Atkins,S Cinta
Pallares,6 Russell E. Burgess,7 Silvia Novello,8 Lesley Tye,9 Paulina Selaru,9 Richard C. Chao,9 Georgio
V. Scagliotti8
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1Washington University School of Medicine, St Louis, MO; 2Catalan Institute of Oncology, Barcelona,
Spain; 3University of North Carolina, Chapel Hill, NC; 4Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins, Cockeysville, MD; 5Southeastern Medical Oncology Center, Goldsboro, NC; 6Hospital de
San Pablo, Oncology, Barcelona, Spain; 7Eastern Carolina Internal Medicine, Pollocksville, NC, USA;
8University of Turin, Orbassano, Italy; 9Pfizer Global Research and Development, La Jolla, CA.
Sunitinib (SUTENT®; SU) an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET,
and FLT3 has shown single-agent antitumor activity in refractory non-small-cell cancer (NSCLC).
Methods: This phase II, multicenter study evaluated SU continuous daily dosing (CDD) in advanced
NSCLC. Primary endpoint: objective response rate (RECIST).
Secondary endpoints: duration of response, progression-free survival (PFS), overall survival (OS), and
safety/tolerability. Results: 47 platinum-refractory stage IIIB/IV NSCLC patients received SU 37.5
mg/day, CDD schedule (4-week cycles). Baseline characteristics: median age 60y (range 37-81); male,
57%; ECOG PS 0/1/2, 49%/49%/2%; adenocarcinoma/squamous cell/other, 53%/15%/32%; # prior
systemic regimens 1/2/>2, 36%/47%/17%. Patients received a median of 3 (range 1-12) cycles.
Most patients (72%) discontinued treatment due to disease progression; however 26% discontinued
due to adverse events (AEs). Partial response was reported in 1 patient, 9 patients (19.1%) had stable
disease (&#8805; 3 months, 8 patients; > 6 months, 3 patients). Median OS was 38.1 weeks (95%
CI: 31.1-NA) and median PFS was 12.3 weeks (95% CI: 8.7-16.0). Sunitinib was well tolerated with
most AEs grade 1-2. Grade 3-4 all-causality, non-hematologic AEs included fatigue/asthenia (17%),
dyspnea (10.6%), hypertension (6.4%) and pleural effusion (6.4%). Four patients (8.7%) experienced
Grade 3 neutropenia and no cases of febrile neutropenia were reported. Conclusions: In this study
continuous daily dosing with sunitinib was well tolerated with a median OS (38.1 weeks) observed in a
heavily pretreated NSCLC population.
PP8
Chemotherapy and melatonin in a lung cancer patient
Banu Eugeniu
Cancer Institute "Ion Chiricuta", Medical Oncology Department, Cluj-Napoca, Romania
Introduction: Melatonin is a cytostatic, immuPPmodulatory and antioxidant agent. Serum concentrations
are significantly lower in advanced non-small cell lung cancer (NSCLC) patients in comparison with
healthy individuals.
Purpose: We present the case of a metastatic NSCLC patient treated chemotherapy and melatonin
combination. The endpoints were disease-specific and progression-free survival, response and toxicity.
Method: The patient decided himself to start melatonin treatment after diagnosis. It was available
without medical prescription, all costs being supported by the patient. The full consent of the patient's
family was obtained.
Results: A man aged of 61 years presented in May 2006 a pyramidal syndrom with signs of intracranial
hypertension. The computed tomograph (CT) scan showed a large solitary fronto-parietal brain
metastasis and a primary lung tumor with mediastinal lymph nodes. The patient presented a poor
Karnofsky performance status (PS) of 60%. A suboptimal brain surgery was performed, followed by
external radiotherapy. Microscopic examination confirmed the presence of an undifferentiated
squamouscarcinoma.
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Post-operatively, a chemotherapy combining gemcitabine and clsplatln was administered, four cycles
every 21 days. Melatonin 10 mg orally, was taken two hours before bedtime. PP major toxicities were
observed, an impressive PS amelioration (100%) was obtained. Disease remained stable for 9 months.
The patient died 12 months after diagnosis. PP signs of cerebral progression were observed.
Conclusion: Melatonin at pharmacological concentration and standard chemotherapy combination was
effective, a longer disease-specific and progression-free survival was obtained. Combination was well
tolerated, the quality of life was improved.
PP9
The distant results of radical treatment of hereditary pathogenic variant of lung cancer
patient.
Shutkin V., Imianytov E., Brenister S.
Moldavian Oncology Institute, Moldova, Chisinau Oncology Institute IN.N.Petrov" S-Petersburg, Russia.
Introduction: In 1994 as a result of complex clinical investigation was advanced and theoretically
founded the conception of two basic pathogenic variants of lung cancer: hereditary (I) and ecologic (II)
(V.Shutkin). The clinical evaluation of lung cancer with present hereditary factor was considered as
hereditary pathogenic variant (I group), the clinical evaluation of control group was considered ecologic
pathogenic variant (II group).
Purpose: The purpose of investigation was the studying of distant results of radical treatment of
hereditary pathogenic variant of lung cancer patients. All material was in prospective study.
Material: It was studied the distant results by 217 patients I group and
807 patients II group which supported radical surgery.
Results and Conclusion: based on our data the 1 year survive the I group patents 1,3 time less
comparative to II group (66,8% against 89,0%), 2 years - 1,6 time less (49,5% against 77,8%), 3
years - 1,7 time less (38,8% against 64,9%), 5 years - 1,8 time less (28,3% against 64,9%), 10 years -
3,4 time less (10,7% against 35,8%).
The fact of hereditary affection radically changes the biologic essential of the tumor, in spate of the fact
that the leading factors which determine the peculiarities of cancer evolution such as localization,
morphologic structure and type of its grouse in both pathogenic groups are approximately identical.
PP 10
Hypomethylation of retrotransposable elements in NSCLC
George Xinarianos1, Alexandros Daskalos1, Georgios Nikolaidis1, Paraskevi Sawari2, Adrian Cassidy1,
Roubini Zakopoulou1,2, Athanasios Kotsinas2, Vassilis Gorgoulis2, John K Field1, & Triantafillos
Liloglou1
1Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, School
of Cancer Studies, Liverpool UK; 2 University of Athens Medical School, Histology-Embryology Lab,
Molecular Carcinogenesis Group, Athens, Greece
Introduction: LINE-1 and Alu elements are non-LTR retrotrsansposons, comprising together over 30%
of the human genome. Hypomethylation of these elements has been reported in human tumours and is
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actually used as a measure of global hypomethylation. Objective/Purpose: The aim of this study was to
investigate the potential active role for hypomethylation-mediated reactivation of retroelements in
genomic instability and apoptosis. or whether LINE and SINE hypomethylation is just a passive
consequence of the epigenetic reprogramming of cancer cells. Method: DNA from NSCLC tissue and
adjacent normal lung was treated with sodium bisulphite and subjected to Pyrosequencing-based
methylation assays. The expression levels of the LINE-1 and Alu-PV elements were studied using qPCR
(real time) assays. Genetic instability was determined employing fluorescent PCR-based microsatellite
assays. Apoptosis was assessed utilising TUNEL assays. Results and Conclusion: We demonstrate that
methylation levels of LINE-1 and Alu sequences decrease significantly
(p=7.7&#61620;10-14 and 9.6&#61620;10-7 respectively) in primary non-small cell carcinomas
compared to the corresponding adjacent tissues. The methylation indices of the two elements
correlated (p=0.006), suggesting a possible common mechanism for their methylation maintenance.
Moreover, hypomethylation of both elements was associated with increased genomic instability (LINE,
p=7.1&#61620;10-5; Alu: p=0.008) while LINE-1 hypomethylation also correlated with apoptosis
(p=0.028). The reduction of the methylation index of LINE-1 and Alu following treatment of five lung
cell lines with 5-aza2'-deoxycitidine, consistently resulted in increased expression of both elements. Our
data point towards an active role for LINE-1 and Alu hypomethylation-mediated reactivation in lung
cancer development.
PP 11
Cancer diagnosis in a first degree relative and lung cancer risk: results from a multicentre
case control study of early lung cancer in Europe (EUELC)
Adrian Cassidv", Jessica Balsarr", Aurelien vesirr', Jean-Francois Timsif, Christian Brarnbilla'', John K.
Held' on behalf of the EUELC Consortium
1 University of Liverpool, Department of Surgery & Oncology, Liverpool, U.K. 2 INSERM U823, Albert
Bonniot Institute, Grenoble, France 3Univ Joseph Fourier, Grenoble, F-38041 France
Introduction: Familial clustering can occur between cancers at different sites: a pattern which indicates
that cancer could be considered as a broad phenotype with shared genetic factors. Here, we report
results from a multicentre case-control study of early lung cancer (EUELC), with particular emphasis on
cancer diagnosis and the risk of lung cancer. METHOD: Resected lung cancer cases were recruited in 15
centres in 8 European countries from 2002 through 2006 together with controls, matched to cases on
sex and age (+/- 5 years). A standardized questionnaire was used to collect demographic and lifestyle
information. Multivariate regression models were used to estimate the odds ratios and 95% confidence
intervals. RESULTS: Our final database contained 2045 subjects (733 cases). Cases were more likely to
have at least a first degree relative with lung cancer (OR=1.55 [1.19 - 2.03]; p=O.OOl). However, this
association disappeared when adjusting on significant environmental variables (OR=1.32 [0.96 - 1.82];
p=0.09). Cases under 55 years-old at diagnosis (16.9%) were more likely to have a first degree relative
undergoing an early onset lung cancer (OR=5.58 [1.51 - 20.67]; p=0.02). The association remained
significant when adjustment variables were entered (OR=4.72 [1.02 - 21.90]; p=0.046).
CONCLUSIONS: Results of this large European study are consistent with previous biological findings
assuming a possible hereditary component in lung cancer risk.
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PP 12
Lung cancer screening with spiral CT: Scientific and policy issues
Stephen W Duffy1, John K Field2, Robert A Smith3, David Whynes4
1Cancer Research UK Centre for Epidemiology, Mathematics & Statistics, Queen Mary University of
London. 2Roy Castle Lung Cancer Research Programme, Cancer Research Centre, University of
Liverpool, Liverpool, UK. 3American Cancer Society, Atlanta, USA. 4University of Nottingham, UK.
The most effective way to control lung cancer is by smoking cessation, however, even after quitting the
risk of developing lung cancer remains high, furthermore, lung cancer in non-smokers is also a public
health problem. Lung Cancer screening utilising LDCT is currently being assessed in a number of trials,
in the USA, Netherlands, Italy and France.
Currently we are awaiting the outcome of two major RCT Trials; the NLST and NELSON. A total of
74,000 subjects worldwide have been randomised into these trials, however, the largest trial won't
report for seven years.
Pooling of data from current trials would provide a result, a year earlier; if the UK contributed to a trial
of similar size as NELSON, a result would be expected in five years. There have been concerns that
even if a trial provided a positive result, the cost of implementation would be too high. An economic
evaluation was commissioned by the NCRI and with assumptions similar to the power calculations in
the current RCT trials and using NHS unit cost estimates for the procedures, an estimate of £14,000 per
life saved was calculated, which is well within the NICE criterion of £30,000. In fact screening a very
high risk group would increase the cost effectiveness. The collaborative concept for the pooling of
international data on LDCT was agreed by all of the major tria lists in the 'Liverpool Statement 2005
(JTO 1: 497-8, 2006).
PP 13
CT Colonography: a new route to the lung cancer clinic
Dr Sarah Gwynne1, Dr Anita Pandit2, Dr Richard Winter3, Dr Louise Hanna1
l.Velindre Cancer Centre, Velindre Hospital, Department of Clinical Oncology, Cardiff, UK; 2. Cwm Taf
NHS Trust, Royal Glamorgan Hospital, Department of General and Respiratory Medicine, Ynysmaerdy,
L1antristant, UK, 3. Cwm Taf NHS Trust, Royal Glamorgan Hospital, Department of Diagnostic
Radiology, Ynysmaerdy, L1antristant, UK.
CT colongraphy, lung cancer, early detection Introduction CT colonography (CTC) is a non-invasive
technique which is used increasingly to investigate colonic symptoms, particularly in elderly/unfit
patients. Incidental extracolonic findings are detected in up to 58% of cases, and 3.7% of cases have
serious pathology. The whole colon is imaged during CTC and therefore the lower lungs are also
visualised.
Objective/purpose: To report outcomes of patients referred to the lung cancer multidisciplinary team
(MDT) who underwent CTC for bowel symptoms and incidentally had radiological findings suggestive of
lung cancer.
Method: MDT and case note review.
Results/conclusion: During February and March 2008, four patients were referred to the lung cancer
MDT following CTC for bowel symptoms (age range 74-87 years). None were found to have large bowel
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cancer but all had lung abnormalities suggestive of lung cancer (2 right lower lobe, 2 right middle lobe).
All patients completed lung staging including a full CT thorax, and in each, a histological diagnosis of
non small cell lung cancer was obtained. All patients were assessed by a lung cancer physician and an
oncologist. PP patient was deemed suitable for radical treatment because of co-morbidity, inadequate
lung function or tumour stage. CTC is leading to an increased number of extracolonic pathologies being
detected and represents a new route of referral to our lung MDT. In this series however, PP patient
was suitable for radical treatment. Increased anxiety and morbidity for patients need to be balanced
against the possibility of future lives saved with earlier detection of cancers.
PP 14
DlRAS3 is hypermethylated in NSCLC
Soultana Markopoulou1, Alexandros Daskalos1, George Nikolaidis1, George Xinarianos1, Dimitra
Vaggeli2, Kostantinos Gourgoulianis3,John K Field1, Triantafillos Liloglou1
1 Roy Castle Lung Cancer Research Programme, The University of Liverpool, School of Cancer Studies,
Liverpool UK. 2 University of Thessaly Medical School, Department of Pathology, Larissa, Greece
3 University of Thessaly Medical School, Department of Pulmonary Medicine, Larissa, Greece
Introduction: Aplysia Ras Homologue I (ARHI), also referred to as DIRAS3 and NOEY2, is a maternally
imprinted gene. Downregulation of ARHI occurs in 60% of ovarian and breast carcinomas and loss of
its expression is associated with progression of breast cancer. Decreased ARHI expression has also
been observed in various other cancers. Objectives. To examine the possible epigenetic deregulation of
DIRAS3 in NSCLC. Methods. We investigated the expression and promoter methylation at two locations
(designated CpG1 and CpG2) of this gene in 95 paired (normal/tumour) lung tissue samples from
patients with NSCLC and in 10 lung cancer cell lines.
Pyrosequencing with methylation specific primers was performed for all tumour samples and gene
expression was assessed with a real-time PCR assay. Results and conclusions. ARHI was found to be
imprinted in normal adjacent lung tissue. We defined a hypermethylation threshold: 95% RR
=mean±3&#61620;SD of the normal lung values. 38/95 (40%) of tumour samples were
hypermethylated at CpG1 and 15/95 (16%) were hypermethylated at CpG2.
CpG1 methylation index correlated with patient age, (Kendal's tau_b =0.177, p=O.Ol1). CpG1
methylation was comparatively analysed in a subset of 48 samples with other molecular information. In
this set it inversely correlated with LINE-1 methylation (Kendal's tau_b =-0.268, p=0.008). It also
correlated strongly with genomic instability (Kendal's tau_b=-0.268, p=7.1&#61620;10-6). All cancer
cell lines were hypermethylated at CpG1, while CpG2 is either hyper or hypomethylated. We conclude
that DIRAS3 hypermethylation is frequent in NSCLC and thus may be important to the development of
the disease.
PP 15
qMSP assay development for early lung cance detection
Georgios Nikolaidis, Soultana Markopoulou, Alexandros Daskalos, George Xinarianos, John K Field, &
Triantafillos Liloglou Roy Castle Lung Cancer Research Programme, University of Liverpool, School of
CancerStudies, Liverpool UK.
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Introduction: DNA methylation abnormalities is a frequent phenomenon in human lung cancer, thus it is
suggested that DNA methylation-based biomarkers may assist in diagnosis, prognosis and therapeutic
stratification. Although a lot of data has already been produced, the spectrum of DNA methylation
markers with the high potential in clinical use is not yet clear. We previously screened 48 primary non-
small cell lung carcinomas using pyrosequencing-based assays for promoter methylation of 21 genes
including p16, RARb, MGMT, , CYGB, RASSF1, TMEFF2, p73, CCNA1, etc. Objectives. To develop assays
with high sensitivity and specificity enabling the detection of abnormally methylated promoters in
sputum as a means of assisting early lung cancer diagnosis. Method. DNA was treated with sodium
bisulphite and subjected to quantitative methylation specific PCR (qMSP) assays. Results and
Conclusions: We selected six genes (p16, RARb, MGMT, CYGB, TMEFF2, p73) to form the first panel of
markers. We developed qMSP assays utilising MGB probes in order to specifically and quantitatively
amplify methylated copies of these promoters. The optimisation of the assays focused on primer/probe
ratio, thermal profile, DNA input and unmethylated control multiplexing ability. We have reproducibly
detected methylated copies in 1:2000 dilution with unmethylated DNA while higher dilutions cause
significant loss of reproducibility. We are currently screening DNA from sputum from the retrospective
case-control component of the Liverpool Lung Project in order to validate the use of this panel in
sputum for early detection purposes.
PP 16
Sp1 regulates expression of TAp73_ isoform in lung cancer cell lines
Logotheti stella', Michalopoulos Ioannis', Melino Gerry', Kossida sotla', Dimitrios Mikas1, John K Field2,
Triantafillos Liloqlou', Zoumpourlis Vasills'
lBiomedical Application Unit, Institute of Biological Research and Biotechnology, National Hellenic
Research Foundation, 48 Vas. Constantinou Ave, 116 35 Athens, Greece 2Roy Castle Lung Cancer
Research Programme, The University of Liverpool, School of CancerStudies, Liverpool UK.
Introduction: p73, a recently discovered p53 homologue, presents a large number of p73 isoforms with
obscure role in cancer, grouped mainly in TAp73 isoforms and _p73 lsoforrns, derived from extrinsic
(P1) and intrinsic (P2) promoter of p73 gene respectively. The switch from TA to _ isoforms
transcription by alternative regulation of P1 and P2 promoters is of highly importance, since it has been
suggested that TA/_ ratio affects the ultimate p73 result in cancer progression.
Objectives: To investigate the dependence of P1 promoter activity on the transcription factor Spl.
Methods: Bioinformatic analysis P1 promoter for transcription factor motifs was followed by EMSA
assays on selected promoter regions. Western blotting analysis of TAp73 and Sp1 proteins was carried
out in 16 lung cell lines.
Results and Conclusions: We have identified four regions, highly conserved in mouse and human P1
promoter, that contain Sp1 sites, spanning from -240 to -210 bps, -64 to -31 bps, -20 to -1 bps and -3
to +19 bps relative to transcription start site. Three of these regions were shown by EMSAs to bind
endogenous Sp1 in the cell lines examined. We have also found that TAp73_ is the abundant TA
isoform in all lung cancer cell lines tested, presenting an expression pattern similar to that of Spl. Thus,
Sp1 is likely to determine the usage of P1 promoter in lung cancer cell lines and, therefore, the relative
abundance of various p73 isoforms.
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PP 17
Genetic changes in plasma &WBC DNA in lung cancer and controls
X Y Xue1, M D Teare2, P J Woll1*
l " International Lung Cancer Conference
1Academic Unit of Clinical Oncology and 2Mathematical Modelling & Genetic Epidemiology, University of
Sheffield, UK Key words: Circulating cell-free DNA; lung cancer; mutations.
Introduction: Survival from lung cancer could be improved significantly if more patients could be
diagnosed at an early stage when suitable for surgical resection.
Low levels of tumour-associated genetic alterations have been found in the circulating cell-free DNA
(CFDNA) of lung cancer patients, showing promising potential for early clinical diagnosis, prognosis and
disease monitoring.
Method: We evaluated the QIAGEN QIAamp kit and developed a new triton/heat/phenol extraction
protocol for CFDNA extraction. Leucocyte and CFDNA was isolated from 200 lung cancer patients and
controls in the ReSoLuCENT study. CFDNA was quantified by SYBR real-time PCR assay. After whole
genome amplification, DNA from cases and paired controls was screened for TP53 (exons 2-11) and
KRAS (exons 2-3) mutations using PCR-SSCP and confirmed by sequenceanalysis.
Results and conclusion: The efficiency of CFDNA extraction was < 20% using the standard QIAamp
protocol and around 45% using the new method (p<O.OOOl). Difference in the levels of plasma CFDNA
concentration between lung cancer cases and paired controls did not achieve significance, but PCR-
SSCP for TP53 and KRAS mutations showed different patterns in cases and in controls; sequencing
analysiswill be done to elucidate this.
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Three methods to study p16 promoter methylation in NSCLC
G. Venturini, S. Bisanzi and F. Carozzi
CSPO, Scientific Institute of Tuscany Region, Analytical Cytology and Biomolecular Unit, Florence, Italy.
Introduction: Aberrant methylation in the promoter region of many genes has been associated with
transcriptional inactivation of tumor suppressor genes in human cancers. The inactivation of plGINK4A
gene by promoter hypermethylation is probably one of the earliest events in lung cancer.
Objective: Analyze the methylation profile of pIG promoter region in NSCLC using three different
methods to understand if there was a correlation between the methylation of specific CpG islands and
NSCLC.
Methods: Genomic DNAwas obtained from 30 lung tumor tissues (15 Adc and
15 SCC); after the treatment of DNA with sodium bisulphite the specimens were subjected to
a methylation-specific PCR (MSP), a quantitative MSP and pyrosequencing.
Results and conclusion: With the three methods it was possible to evaluate the methylation pattern of
14 CpG islands in the promoter region of pIG.
Pyrosequencing appeared for our purpose the most useful method, combining a good sensitivity and
reproducibility over time. Considering the whole analyzed region the SCC resulted more methylated
than Adc and in particular in this group the region which corresponded to MSP forward primer was the
most methylated. So understanding the methylation pattern of this gene could be important for a more
aimed therapeutic approach.
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Expression and methylationof globin family genes in lung cancer
Urszula Babiszkiewicz, Triantafillos Liloglou, John K Field & GeorgeXinarianos
lRoy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, School
of CancerStudies, Liverpool UK
Introduction: Globins are proteins involved in pathways associated with oxygen transport and
metabolism. Although the exact role of cytoglobin (CYGB) and neuroglobin (NGB) remains elusive,
CYGB underexpression and methylation in certain cancers, including lung cancer, suggests CYGB may
function as a tumour suppressor gene.
Objective/Purpose: Our aim was to determine the expression levels of CYGB, NGB and myoglobin (MB)
in lung cancer and analyse the methylation status of their promoters in normal bronchial epithelial, lung
cancer and fibroblast cell lines.
Method: DNA samples were extracted from 24 cell lines (15 lung cancer, 7 normal bronchial epithelial
and 2 lung fibroblast), treated with sodium bisulphite and subjected to Pyrosequencing-based
methylation assays. Expression in the presence and absence of 5'azadeoxycitidine and trichostatin A
was carried out using qPCR (real time) assays.
Results and Conclusion: Our data demonstrated that CYGB expression is reduced in lung cancer cell
lines and this underexpression is related to promoter methylation. NGB expression was detected at
high levels only in small cell lung cancer cell lines. This was inversely correlated with the methylation
status of the NGB promoter. MB was found to be overexpressed in the lung cancer cell lines studied.
MB promoter region doesn't contain any CpG islands and therefore it is unlikely to be regulated by DNA
methylation. Treatment with 5'azadeoxycitidine and trichostatin A restored normal expression levels of
both CYGB and NGB in most of the cell lines suggesting that globin family proteins may be involved in
the molecular pathogenesis of lung cancer.
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The LLP risk model: Predicting lung cancer's risk in the presence of missing factors
Olaide Raji1, Stephen Duffy2 and John Field11.
Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre,
Liverpool UK 2. Cancer Research UK Centre for Epidemiology, Mathematics and Statistics Wolfson
Institute of Preventive Medicine, London UK
Background: Risk prediction model is an essentially useful tool for identifying individuals at high risks of
developing a disease and thus enhances early diagnosis. The Liverpool Lung Project (LLP) has
previously developed and internally validated a risk prediction model for lung cancer. The model
identified five epidemiological risk factors (smoking duration, prior diagnosis of pneumonia,
occupational exposure to asbestos, prior diagnosis of malignant tumour, family history of lung cancer)
as important predictors of lung cancer risk. Whilst these factors are normally easily and readily
available, a number of patients may not have a complete information profile necessary for the
estimation of their absolute risk.
This thus required an extension of the model when data for one or more of these factors is not
available.
Aim: To extend the LLP risk model for use in patients with an incomplete information profile by
providing the 'best' models for all possible combinations of the five risk factors.
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Method: Data on 579 newly diagnosed lung cancer cases and 1157 age- and sex-matched population-
based controls were randomly divided into training and validation samples for the modelling exercise.
The training sample was used to fit the best subsets conditional logistic regression. All the 'best' 2, 3,
and 4 factors models selected using the Mallow's Cq criterion were then separately evaluated in the
validation dataset using the area under the ROC (ReceiverOperating Curve).
Results: Results from the model fitting, validation and both samples will be presented to summarise the
measures of fit and relative risks. The absolute risks of lung cancer within a 5-year period, resulting
from each of the 'best' subsets models, for hypothetical individuals will be presented and compared.
Conclusion: This extension of the LLP risk model to missing data situation would be useful in primary
care setting where such model is required as the first stage in an early detection strategy of a high-risk
population.
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Sunitinib and erlotinib in advanced/metastatic NSCLC
Ramaswamy Govindan/ George Blumenschein/ Harry J.M Groen," Aleksandra Szczesna," Janos
Strausz." Jesus Montesinos,6 Lesley Tye/ Richard C. Chao/ Giorgio V. Scagliotti 8
lAlvin J Siteman Cancer Center ,Washington University School of Medicine, St Louis, MO; 2University of
Texas, MD Anderson Cancer Center, Houston, TX; 3University Medical Center Groningen, the
Netherlands; "Reqional Lung Diseases Hospital, Otwock, Poland; 5 Koranyi National Institute for
Pulmonology, Budapest, Hungary; 6Corporacion Sanitaria Parc Tauli, Sabadell-Barcelona, Spain; 7Pfizer
Global Research and Development, La Jolla, CA; 8University of Turin, Department of Clinical and
Biological Sciences, Orbassano (Turin), Italy
Resistance to single-target therapies in NSCLC occurs by bypassing inhibited signal pathways (SPs) via
parallel, overlapping SPs, thus rational combinations inhibiting multiple SPs may be less prone to drug
resistance. Vascular endothelial growth factor receptor (VEGFR) and human epidermal growth factor
receptor (EGFR/HER1) share common downstream SPs exerting direct/indirect effects on tumor
vasculature are important antiangiogenic targets. Co-inhibition of VEGFR-EGFR in preclinical models
showed significantly greater antitumor activity over inhibition of either SP alone. Sunitinib (SUTEN-r®)
an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET, and FLT3 has shown
single-agent antitumor activity in refractory NSCLC. Preliminary results (SUN1058) of a randomized,
multicenter, phase II trial evaluating sunitinib (SU) + erlotinib (E) found 2/12 patients had durable
partial responses and SU + E was well tolerated. SU + E is a novel VEGFR-EGFR inhibitor combination
that may confer additive/synergistic clinical benefit in patients with advanced NSCLC.
Methods: SUN1087 is a global randomized, double-blind, multicenter, pivotal, phase III trial of E ± SUo
Approximately 950 patients with stage IIIB/IV advanced NSCLC, an ECOG performance status of 0-1
and a minimum of one prior platinum-based treatment regimen will be randomized to E 150 mg/day
plus SU 37.5 mg/day or E 150 mg/day plus placebo. Primary endpoint is overall survival; secondary
endpoints include progression-free survival, objective response rate, 1-year survival, duration of
response, adverse events, patient-reported outcomes.
Results/Conclusions: Enrollment is ongoing. SU + E may be a novel VEGFR-EGFR co-inhibition
treatment strategy in patients with advanced/metastatic NSCLC.
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TP73 promoter methylation in NSCLC
Alexandros Daskalos, Georgios Nikolaidis, George Xinarianos, Adrian Cassidy, John K Field, &
Triantafillos Liloglou
Roy Castle Lung Cancer Research Programme, University of Liverpool, School of Cancer Studies,
Liverpool UK.
Introduction: TP73 expression is controlled by two promoters resulting in different isoforms. Promoter
Pl controls products containing the TA domain (TAp73). Promoter P2 is located in intron 3 and controls
the expression of proteins lacking the TA domain (&#916;Np73). The full TAp73 proteins induce cell
cycle arrest and apoptosis. &#916;Tp73 isoforms inhibit apoptosis either by direct inhibition of TAp73
or through inhibition of p53-mediated transcription. &#916;Np73 overexpression in lung cancer
correlates with poor prognosis.
Objectives: To reveal the extent of epigenetic regulation of the two TP73 promoters in NSCLC.
Methods. We developed Pyrosequencing assays to screen bisulphite treated DNA from 90 primary
NSCLC and normal adjacent tissues.
Results and Conclusions: Hypermethylation of Pl was found in 24/90 (26.7%). Hypomethylation of P2
was found in 56/82 (68.3%) tumour samples. There is PP correlation between the methylation status of
the two promoters suggesting that aberrant hyper- and hypomethylation is likely caused by
mechanisms possibly involving different DNMTs. Interestingly, hypermethylation of the Pl promoter
correlated with enhanced H2AX staining indicating increased DNA strand breaks (Spearman's rho,
p=0.003). In addition, hypomethylation of P2 correlated with increased genomic instability as expressed
by the fractional allele loss (FAL) values (Spearman's rho, p value=0.002). Our data suggest that DNA
methylation at the Tp73 promoters is frequently aberrant in NSCLC. It is likely that these abnormal
methylation patterns in lung carcinomas are, at least partially, responsible for the transcriptional
regulation of the different p73 isoforms bearing tumour-suppressor or oncogenic activity.
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Molecular Signatures and Clinical Outcome in Lung Cancer
Garry Beran Garry Beranl, Andrew Thomasl, David Blowersl, Fredrik Nyberg2, Lars Holmberg3, Mats
Lambe3, Anders Berglund3, Johan Botling4, Patrick Micke4, Karolina Edlund4, Anders Isaksson5, Hanna
Gbransson5, Michael Bergqvist6, Simon Ekman6, Elisabeth Stahle7, Kristina Lamberg8
1 AstraZeneca, Alderley Park, UK,
2 AstraZeneca, Molndal, Sweden,
3 Regional Oncologic Centre, Uppsala University Hospital,
4 Dept. of Geneticsand Pathology, Uppsala University Hospital,
5 Dept. of Medical Sciences, Uppsala University,
6 Department of Oncology, Uppsala University Hospital
7 Department of Cardiothoracic Surgery, Uppsala University Hospital,
8 Department of Pulmonary Medicine, Uppsala University Hospital
Survival in lung cancer is greatly enhanced by early detection and treatment, but the majority of
patients at diagnosis have advanced disease. Gaining better understanding of the molecular profiles of
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patients with good and poor prognosis, especially in the post surgery early disease setting, is critical to
address this high mortality disease.
Historically, molecular data from single nucleotide polymorphism (SNP) genotyping and gene expression
microarray analysis has been generated in isolation or lacks critical survival data for robust analysis.
We begin to address this gap by identification of genomic aberrations such as DNA copy number
changes, loss-of-heterozygosity (LOH), and monitoring of thousands of mRNA transcripts with
additional mutation screening combined with survival outcome relating to stage, smoking status and
diagnosis.
To date we have profiled 60 patient samples from the Swedish Lung Cancer Registry on the Affymetrix
HG_U133_Plus2 & 250K Nsp microarrays. These were selected as two groups, 30 short and 30 long
term survivors, based on availability of high quality fresh frozen samples with corresponding patient
registry records and checks to ensure that no other group bias was introduced.
For most patients there is corresponding non-malignant tissue. Additional mutation analysis was
performed on p53, EGFR and KRAS.
Gene copy number of EGFR was evaluated by fluorescent in situ hybridisation (FISH).
This integrated approach provides a powerful tool to identify novel prognostic molecular signatures and,
in the long term, gain better understanding of underlying tumourigenic mechanisms and identification
of novel therapeutic targets.
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A pilot study to explore lung cancer early detection and clinical intervention in a primary
care setting in Knowsley, Merseyside
MJ Ashton 1, C Mimnagh2, D Forrest', JK Field3,
1 Knowsley Primary CareTrust, Liverpool UK. 2 Wingate Medical Practice, Knowsley, Liverpool, UK. 3 Cancer
Research Centre, University of Liverpool, UK.
Knowsley is ranked as the 8th most deprived local authority in England (IMD, 2007) and its 150,000
residents have amongst the highest lung cancer incidence and mortality rates in the UK.
The high mortality rate is due to the majority of lung cancer patients being diagnosed at an advanced
stage. Efforts to limit the use of tobacco are currently the most effective method to reduce the burden
of lung cancer. Despite major efforts to reduce smoking rates, lung cancer remains the largest cancer
killer. Therefore, policies which encourage individuals to quit smoking must coincide with programmes
to detect lung cancer before the onset of clinical symptoms.
Recently, there has been widespread interest in moving the focus of lung cancer detection from
secondary to primary care. Knowsley Primary Care Trust has commissioned a pilot study to determine
if a validated screening approach for lung cancer in the primary care setting could be used to identify
people who would benefit from more intensive diagnostic examination and from early referral for
surgical intervention. This may result in substantial reductions in the high mortality rate from this
disease. This presentation will describe this pioneering initiative and present preliminary findings.
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